1316216-05-3Relevant articles and documents
Mercapto compounds as histone deacetylase inhibitors and uses thereof
-
, (2020/03/29)
Experimental results show, that the compound shown by the invention has high blood-brain barrier permeability, on normal cytotoxic low, potential cardiac toxicity, and higher blood-brain barrier permeability of, on a cell model as a compound shown, or a pharmaceutically acceptable salt, ester or a prodrug, of the compound as a high-efficiency low-toxicity anti-tumor or neurodegenerative disease therapeutic agent shown in the invention. The compound has high blood-brain barrier permeability . The compound of the present invention has higher blood-brain barrier permeability as shown in the development prospect (I) of, a: therapeutic agent for high-efficiency and low-toxicity antitumor or neurodegenerative diseases.
PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USE THEREOF
-
, (2018/06/12)
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND EPOTHILONE AND METHODS OF USE THEREOF
-
, (2018/05/24)
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an epothilone, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.